Clinical Trial

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Name: Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer — clinical trial record (NCT04322617)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATHENA

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2020-03-24; most recent amendment 2024-06-01.

Trial Details

NCT Number	NCT04322617
Lead Sponsor	Hunan Province Tumor Hospital
Conditions	Non-small Cell Lung Cancer
Enrollment	1,200 participants
Start Date	2020-03-24
Primary Completion	2028-03-24 (estimated)
Study Completion	2029-03-24 (estimated)
Updated on ClinicalTrials.gov	2024-06-04